Singapore, Nov. 13 -- Germany-based Fresenius SE & Co. KGaA has entered an exclusive development agreement with China's WuXi Biologics, a leading global contract organisation for research, development and manufacturing. The agreement significantly expands and accelerates Fresenius' biosimilars pipeline while preserving strategic flexibility and disciplined capital allocation. It provides access to a scalable pathway to increase the portfolio from 29 marketed and pipeline molecules today to up to 66 molecules, addressing more than €370 billion in originator list-price-based-sales, extending Biopharma growth in the long term beyond its 2030 ambition.

The agreement provides Fresenius with exclusive access to up to 37 identified biosim...